John Wrangle to Cell Line, Tumor
This is a "connection" page, showing publications John Wrangle has written about Cell Line, Tumor.
Connection Strength
0.187
-
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013 Nov; 4(11):2067-79.
Score: 0.080
-
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv. 2019 09; 5(9):eaax6352.
Score: 0.030
-
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 11 01; 24(21):5250-5260.
Score: 0.028
-
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
Score: 0.027
-
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2015 Jan 01; 6(1):56-70.
Score: 0.022